Luteolin 7-O-glucuronide (Synonyms: Luteolin 7-glucuronide)

Name: Luteolin 7-O-glucuronide
Brand: MedChemExpress
SKU: HY-N1463
Rating: 5.0 (3 reviews)

Cat. No.: HY-N1463 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively.

For research use only. We do not sell to patients.

CAS No. : 29741-10-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Luteolin 7-O-glucuronide:

Luteolin 7-O-glucuronide (Standard) Get quote

3 Publications Citing Use of MCE Luteolin 7-O-glucuronide

Cell Proliferation/Viability Assay

: Luteolin 7-O-glucuronide purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Sep;4(9):1231-1248.; 3,4-Dicaffeoylquinic acid (Dicaffeoylquinic acid). Quantification of SA-β-Gal assay of UV-B-irradiated IMR90 fibroblasts, treated with the indicated compounds at 1 μM concentration or 10 μg/mL for HK.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

View All Isoforms

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

Biological Activity
Purity & Documentation
References
Customer Review

Description

Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively^[1].

IC₅₀ & Target

MMP-1

17.63 μM (IC₅₀)

MMP-3

7.99 μM (IC₅₀)

MMP-8

11.42 μM (IC₅₀)

MMP-9

12.85 μM (IC₅₀)

MMP13

0.03 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	CC₅₀	>100 μM Compound: 21	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33667099]
RAW264.7	IC₅₀	>100 μM Compound: 21	Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 33667099]

In Vitro

Luteolin 7-O-glucuronide (0-50 μM, 2 h) inhibits NO production and mRNA expression of inflammatory mediators (COX-2, IL-6, IL-1β, and TNF-α) in LPS-stimulated RAW 264.7 macrophages^[2].
Luteolin 7-O-glucuronide (0-50 μM, 2 h) inhibits NF-κB, p38, and JNK activation in LPS-stimulated RAW 264.7 macrophages^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	LPS-stimulated RAW 264.7 macrophages
Concentration:	0-50 μM
Incubation Time:	2 h
Result:	Inhibited phosphorylation and degradation of IκB. Inhibited phosphorylation of p38 and JNK.

In Vivo

Luteolin 7-O-glucuronide (0.3-3 mg/kg, p.o., once daily for 5 days) improves depression-like and stress coping behaviors in the tail suspension test and forced swimming test in a mouse sleep deprivation model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mouse sleep deprivation model^[3]
Dosage:	0.3-3 mg/kg
Administration:	p.o., once daily for 5 days
Result:	Reduced the increased immobility time in sleep-deprived mice. Reduced the increased plasma corticosterone level. Reduced TNF-α and IL-1β level and increased BDNF mRNA expression in the hippocampus of sleep-deprived mice.

Molecular Weight

462.36

Formula

C₂₁H₁₈O₁₂

CAS No.

29741-10-4

Appearance

Solid

Color

White to light yellow

SMILES

O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=CC(O)=C3C(C=C(C4=CC=C(O)C(O)=C4)OC3=C2)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (270.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1628 mL	10.8141 mL	21.6282 mL
5 mM	0.4326 mL	2.1628 mL	4.3256 mL
10 mM	0.2163 mL	1.0814 mL	2.1628 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (10.81 mM); Clear solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% Methyl cellulose/0.5% Tween-80 in Saline water
Solubility: 15.71 mg/mL (33.98 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (249 KB) HNMR (283 KB) RP-HPLC (246 KB) MS (228 KB)

Handling Instructions (2659 KB)

References

[1]. Crascì L, et al. Correlating In Vitro Target-Oriented Screening and Docking: Inhibition of Matrix Metalloproteinases Activities by Flavonoids. Planta Med. 2017 Jul;83(11):901-911. [Content Brief]

[2]. Cho YC, et al. Anti-Inflammatory and Anti-Oxidative Effects of luteolin-7-O-glucuronide in LPS-Stimulated Murine Macrophages through TAK1 Inhibition and Nrf2 Activation. Int J Mol Sci. 2020 Mar 16;21(6):2007. [Content Brief]

[3]. Ryu D, et al. Luteolin-7-O-Glucuronide Improves Depression-like and Stress Coping Behaviors in Sleep Deprivation Stress Model by Activation of the BDNF Signaling. Nutrients. 2022 Aug 12;14(16):3314. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1628 mL	10.8141 mL	21.6282 mL	54.0704 mL
	5 mM	0.4326 mL	2.1628 mL	4.3256 mL	10.8141 mL
	10 mM	0.2163 mL	1.0814 mL	2.1628 mL	5.4070 mL
	15 mM	0.1442 mL	0.7209 mL	1.4419 mL	3.6047 mL
	20 mM	0.1081 mL	0.5407 mL	1.0814 mL	2.7035 mL
	25 mM	0.0865 mL	0.4326 mL	0.8651 mL	2.1628 mL
	30 mM	0.0721 mL	0.3605 mL	0.7209 mL	1.8023 mL
	40 mM	0.0541 mL	0.2704 mL	0.5407 mL	1.3518 mL
	50 mM	0.0433 mL	0.2163 mL	0.4326 mL	1.0814 mL
	60 mM	0.0360 mL	0.1802 mL	0.3605 mL	0.9012 mL
	80 mM	0.0270 mL	0.1352 mL	0.2704 mL	0.6759 mL
	100 mM	0.0216 mL	0.1081 mL	0.2163 mL	0.5407 mL

Luteolin 7-O-glucuronide Related Classifications

Neurological Disease Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Luteolin 7-O-glucuronide29741-10-4Luteolin 7-glucuronideMMPMatrix metalloproteinasesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Luteolin 7-O-glucuronide (Synonyms: Luteolin 7-glucuronide)

Customer Review

Other Forms of Luteolin 7-O-glucuronide:

Luteolin 7-O-glucuronide Related Antibodies

3 Publications Citing Use of MCE Luteolin 7-O-glucuronide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Luteolin 7-O-glucuronide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Luteolin 7-O-glucuronide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report